✦ LIBER ✦

1209 TREATMENT-EMERGENT VARIANTS FOLLOWING 3 DAYS OF MONOTHERAPY WITH IDX719, A POTENT, PAN-GENOTYPIC NS5A INHIBITOR, IN SUBJECTS INFECTED WITH HCV GENOTYPES 1–4

✍ Scribed by McCarville, J.F.; Seifer, M.; Standring, D.N.; Mayers, D.L.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1186 SAFETY AND ANTIVIRAL ACTIVITY OF AB

✍ Lawitz, E.; Marbury, T.; Campbell, A.; Dumas, E.; Kapoor, M.; Pilot-Matias, T.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 118 KB

876 ACH-3102, A SECOND GENERATION NS5A I

✍ Muir, A.; Hill, J.; Lawitz, E.; Marbury, T.; Robarge, L.; Robison, H.; Hui, J.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 57 KB

P1222 A PHASE II STUDY OF SAMATASVIR (ID

✍ Lawitz, E.; Rodriguez-Torres, M.; Nguyen, T.; Sheikh, A.; Tobias, H.; Galati, J. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 74 KB

A randomized, double-blind, multiple-dos

✍ Vince, Bradley; Hill, John M.; Lawitz, Eric J.; O’Riordan, William; Webster, Lyn 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 857 KB